AgoneX Biopharmaceuticals, Inc. intends to advance its product (AGX-201) and its industry unique technology in order to provide patients with a safe and effective treatment for migraine headaches. Once the company has successfully developed our migraine product, the company intends to develop its proprietary technology for additional indications such as Parkinson’s disease, Multiple Sclerosis (MS), Chronic Traumatic Encephalopathy (CTE) and Amyotrophic Lateral Sclerosis (ALS). The company has three (3) issued patents in the U.S. and one (1) issued patent in Japan.

For additional information, please send an email to bd@agonexbio.com.

Parkinson’s Disease is one of the most common neurologic disorders, affecting approximately 1% of individuals older than 60 years and causing progressive disability that can be slowed, but not halted, by treatment. Despite extensive research in the area of PD, the precise pathogenesis remains largely unknown. Parkinson’s Disease is characterized by motor and nonmotor (cognitive and limbic) deficits. The economic burden of Parkinson’s disease is at least $14.4 billion a year in the United States, and the prevalence of Parkinson’s will more than double by the year 2040.